Surgical Ventricular Reconstruction for Heart Failure Is There Life After STICH?⁎⁎Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology by Bonow, Robert O.
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 4 , N O . 7 , 2 0 1 1
© 2 0 1 1 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 1 . 0 6 . 0 0 1E D I T O R I A L C O M M E N T
Surgical Ventricular Reconstruction for Heart Failure
Is There Life After STICH?*
Robert O. Bonow, MD
Chicago, IllinoisI
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bThe major advances in medical therapy that have
occurred over the past few decades have not dimin-
ished the impact of heart failure as one of the
leading causes of death and disability in the devel-
oped countries of the world. Mortality rates remain
high in patients with left ventricular (LV) systolic
dysfunction, even among those receiving evidence-
based medical therapies. Adverse LV remodeling is
continuous and unrelenting in all too many patients
with ischemic or dilated cardiomyopathy.
See page 762
The progressive nature of LV chamber dilation,
with its concomitant neurohormonal activation,
myocardial fibrosis, and hypertrophy, have gener-
ated considerable interest in surgical techniques to
alter LV volume and geometry toward more normal
size, shape, and physiology. During the previous
decade, surgical ventricular reconstruction (SVR)
procedures were developed for this purpose and in
small, unblinded series resulted in improvement in
both LV function and quality of life (1–4). How-
ever, it was uncertain whether SVR combined with
coronary artery bypass surgery (CABG) would re-
sult in improved outcomes of patients with ischemic
cardiomyopathy compared with CABG alone, es-
pecially when combined with evidence-based med-
ical management. This equipoise led to the multi-
center, prospective, randomized STICH (Surgical
Treatment for Ischemic Heart Failure) trial, spon-
sored by the National Heart, Lung, and Blood
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Illinois. Dr. Bonow has reported that he has no relationships to disclose.nstitute, which randomized 1,000 patients to
ABG or to CABG plus SVR (5). Patients in both
roups also received aggressive, evidence-based
edical therapies. The STICH trial reported no
enefit of SVR plus CABG over CABG alone in
erms of mortality, hospitalization, or quality of life
ver a median follow-up period of 4 years. Despite
hese definitive findings, the results of the STICH
rial have engendered considerable discussion and
ontroversy among proponents of SVR (6–9).
Alternative surgical techniques to reshape the left
entricle have also been promulgated. Unlike the
tandard SVR procedure, in which an endocardial
atch is placed before reshaping the ventricle, in
004 Matsui et al. (10) reported early experience
ith a modified method of SVR, termed overlap-
ing left ventriculoplasty (OVLP), in which the
yocardial layers were overlapped without the
lacement of an endocardial patch. Short-term
xperience with this method in small numbers of
atients, with or without associated mitral valve
epair for functional mitral regurgitation (MR), was
avorable in terms of operative mortality, symptom
mprovement, and hemodynamics (10,11). Opera-
ive mortality with this procedure varied between
.0% and 12.5%, compared with 5.0% in patients
reated with CABG plus SVR in the STICH trial
5,10,11).
In this issue of iJACC, Sugiki et al. (12) provide
urther unique information regarding the functional
esults of the OLVP method of SVR. Using a
ombination of echocardiography and positron emis-
ion tomography (PET), the investigators studied LV
unction, volume, and mass along with assessment of
xidative metabolism using carbon-11 acetate. They
eport that the reduction in LV volume and mass after
he surgical remodeling procedure is associated with
oth a reduction in global oxidative metabolism and
n increase in cardiac efficiency or “work metabolic
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 7 , 2 0 1 1
J U L Y 2 0 1 1 : 7 7 1 – 3
Bonow
Editorial Comment
772index” (WMI). These results represent an impres-
sive body of work from an experienced team of
surgeons, cardiologists, and imaging experts. These
apparently favorable results underscore the unique
potential of PET in assessing the effects of medical
or surgical interventions in heart failure. Whether
these results also provide new impetus for further
exploration of the role of surgical remodeling tech-
niques in the treatment of heart failure, however, is
less certain and will require additional evidence.
Equally important would be findings in patients
treated with aggressive medical therapy. In the
current study by Sugiki et al. (12), 7 of 12 patients
(58%) received standard medical therapy for heart
failure in terms of beta-blockers and angiotensin
receptor blockers (ARBs), but 42% did not: 2
patients did not receive beta-blockers, 2 patients did
not receive ARBs, and 1 patient did not receive
either a beta-blocker or an ARB. Spironolactone
was also not consistently used. This is an important
issue because medical therapy for heart failure will
not only improve symptoms and LV systolic func-
tion, but will also improve oxidative metabolism
and cardiac efficiency, as pointed out by the authors
(13–15).
Several caveats are warranted in interpreting the
oxidative metabolism results reported by Sugiki et
al. (12). As noted by the authors, their sample size
was small (N  12), especially considering the
subgrouping of patients according to ischemic and
nonischemic etiologies, and larger numbers of pa-
tients will be needed to draw meaningful conclu-
sions and support these preliminary positive find-
ings. In addition, the follow-up period of 1 month is
too brief to determine the longer term effects on
cardiac function, oxidative metabolism, and work
efficiency. There are other issues worthy of discussion.
It is noteworthy that the carbon-11 acetate data
revealed no change in oxidative metabolism per
gram of tissue (Kmono) from before to after sur-
gery. As the global oxidative metabolism and the
WMI are defined as: global oxidative metabolism
(Kmono)(LV mass) and WMI  [(forward stroke
volume)(systolic blood pressure)(heart rate)]/
Kmono, it is apparent, in the absence of any change
in Kmono, that the decrease in global oxidative
metabolism is driven entirely by the reduction in
LV mass, and the increase in WMI is driven
entirely by the increases in forward stroke volume
and heart rate. Thus, the PET data actually yield
little insight beyond the insights provided by the
echocardiographic data alone. These latter data are
also worthy of further scrutiny.It is uncertain whether LV mass can change as
abruptly within 1 month of surgery as reported by
Sugiki et al. (12), given that the operation does not
actually remove any LV myocardium but simply
folds it upon itself. More likely, the changes in
calculated LV mass are more apparent than real and
reflect the impact on the determination of LV mass of
the significant and immediate reduction in LV volume
stemming from the volume-reducing surgery.
Similarly, the WMI equation may not provide an
accurate evaluation of overall LV work when there
is significant MR because only the forward stroke
volume measured in the LV outflow tract is ac-
counted for. Thus, although it is good to know that
forward stroke volume increased post-operatively (a
true benefit of the operation), it is not certain
whether total LV stroke volume actually increased.
Total LV stroke volume may actually decrease after
elimination of MR. The total stroke volume (for-
ward plus regurgitant) might have been used in the
calculation of the pre-operative WMI had the
authors computed regurgitant volume according to
current societal recommendations (16–18) rather
than a semiquantitative assessment of MR color
flow using the older recommendations of the 1997
American College of Cardiology/American Heart
Association guidelines on echocardiography (19).
Interpretation of the post-operative increase in
heart rate is equally difficult because no patient
received post-operative beta-blockers according to
the surgical protocol, including the 9 patients re-
ceiving these medications pre-operatively. Thus,
the increase in heart rate could reflect, at least in
some patients, the effects of beta-blocker with-
drawal. These issues regarding the post-operative
changes in LV stroke volume and heart rate make it
uncertain whether the increase in calculated WMI
represents a true benefit of surgery.
As the authors note, further experience in larger
numbers of patients with longer follow-up periods
is necessary to determine the relevant role of surgi-
cal OLVP and mitral valve repair in patients with
ischemic and nonischemic LV systolic dysfunction.
The significant reduction in LV end-diastolic and
end-systolic volumes at 1 month after OLVP is an
expected result of an operation designed to achieve
this endpoint. More important would be the effect
on late LV remodeling and whether the changes
and LV volumes and function are sustained with
longer follow-up periods. It is noteworthy that no
long-term data have yet been reported regarding
LV function and clinical outcomes (such as mortal-
ity) in patients undergoing the OLVP procedure,
n
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773including the patients reported initially in 2004 and
2005 (10,11), for whom such data should now be
available. Thus, in the absence of such data and
comparison with a medically treated control group,
the use of OLVP or other forms of SVR remains an
unproven strategy in the management of patients
with heart failure. As far as patients with ischemic
LV dysfunction are concerned, the STICH trial (5)Wechsler AS, Beyersdorf F, Conte
1
1
1
1
1
1
myocardial energetisuch approaches are not superior to CABG alone in
patients who are also receiving aggressive medical
therapy.
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